Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience

Ermelinda de Maio; Adriano Gravina; Carmen Pacilio; Gerardo Amabile; Vincenzo Labonia; Gabriella Landi; Francesco Nuzzo; Emanuela Rossi; Giuseppe D'Aiuto; Immacolata Capasso; Massimo Rinaldo; Brunello Morrica; Massimo Elmo; Massimo Di Maio; Francesco Perrone; Andrea de Matteis

doi:10.1186/1471-2407-5-30

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience

Ermelinda de Maio, Adriano Gravina, Carmen Pacilio, Gerardo Amabile, Vincenzo Labonia, Gabriella Landi, Francesco Nuzzo, Emanuela Rossi, Giuseppe D'Aiuto, Immacolata Capasso, Massimo Rinaldo, Brunello Morrica, Massimo Elmo, Massimo Di Maio, Francesco Perrone, Andrea de Matteis

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (

Original language	English
Article number	30
Journal	BMC Cancer
Volume	5
DOIs	https://doi.org/10.1186/1471-2407-5-30
Publication status	Published - Mar 24 2005

ASJC Scopus subject areas

Oncology
Cancer Research
Genetics

Access to Document

10.1186/1471-2407-5-30

Fingerprint Dive into the research topics of 'Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience'. Together they form a unique fingerprint.

Cite this

de Maio, E., Gravina, A., Pacilio, C., Amabile, G., Labonia, V., Landi, G., Nuzzo, F., Rossi, E., D'Aiuto, G., Capasso, I., Rinaldo, M., Morrica, B., Elmo, M., Di Maio, M., Perrone, F., & de Matteis, A. (2005). Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience. BMC Cancer, 5, [30]. https://doi.org/10.1186/1471-2407-5-30

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients : A single-center experience. / de Maio, Ermelinda; Gravina, Adriano ; Pacilio, Carmen; Amabile, Gerardo; Labonia, Vincenzo; Landi, Gabriella; Nuzzo, Francesco; Rossi, Emanuela; D'Aiuto, Giuseppe; Capasso, Immacolata; Rinaldo, Massimo; Morrica, Brunello; Elmo, Massimo; Di Maio, Massimo; Perrone, Francesco; de Matteis, Andrea.

In: BMC Cancer, Vol. 5, 30, 24.03.2005.

Research output: Contribution to journal › Article › peer-review

de Maio, Ermelinda ; Gravina, Adriano ; Pacilio, Carmen ; Amabile, Gerardo ; Labonia, Vincenzo ; Landi, Gabriella ; Nuzzo, Francesco ; Rossi, Emanuela ; D'Aiuto, Giuseppe ; Capasso, Immacolata ; Rinaldo, Massimo ; Morrica, Brunello ; Elmo, Massimo ; Di Maio, Massimo ; Perrone, Francesco ; de Matteis, Andrea. / Compliance and toxicity of adjuvant CMF in elderly breast cancer patients : A single-center experience. In: BMC Cancer. 2005 ; Vol. 5.

@article{282cd6da73b344fe8eb0c064baf8a77b,

title = "Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: A single-center experience",

abstract = "Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (",

author = "{de Maio}, Ermelinda and Adriano Gravina and Carmen Pacilio and Gerardo Amabile and Vincenzo Labonia and Gabriella Landi and Francesco Nuzzo and Emanuela Rossi and Giuseppe D'Aiuto and Immacolata Capasso and Massimo Rinaldo and Brunello Morrica and Massimo Elmo and {Di Maio}, Massimo and Francesco Perrone and {de Matteis}, Andrea",

year = "2005",

month = mar,

day = "24",

doi = "10.1186/1471-2407-5-30",

language = "English",

volume = "5",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Compliance and toxicity of adjuvant CMF in elderly breast cancer patients

T2 - A single-center experience

AU - de Maio, Ermelinda

AU - Gravina, Adriano

AU - Pacilio, Carmen

AU - Amabile, Gerardo

AU - Labonia, Vincenzo

AU - Landi, Gabriella

AU - Nuzzo, Francesco

AU - Rossi, Emanuela

AU - D'Aiuto, Giuseppe

AU - Capasso, Immacolata

AU - Rinaldo, Massimo

AU - Morrica, Brunello

AU - Elmo, Massimo

AU - Di Maio, Massimo

AU - Perrone, Francesco

AU - de Matteis, Andrea

PY - 2005/3/24

Y1 - 2005/3/24

N2 - Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (

AB - Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment. Methods: We retrospectively reviewed compliance and safety of adjuvant CMF in patients older than 60. The treatment was indicated if patients had no severe comorbidity, a high-risk of recurrence, and were younger than 75. Toxicity was coded by NCI-CTC. Toxicity and compliance were compared between two age subgroups (

UR - http://www.scopus.com/inward/record.url?scp=26844432325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844432325&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-5-30

DO - 10.1186/1471-2407-5-30

M3 - Article

C2 - 15790416

AN - SCOPUS:26844432325

VL - 5

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 30

ER -